ArticleJournal of molecular histology2026
Human chorionic membrane mesenchymal stem cell-conditioned medium activates the SOX18/MECP2 axis to protect against sepsis-induced lung injury.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis-associated acute lung injury represents a severe complication. It is characterized by an overwhelming inflammatory response and the disruption of pulmonary barrier function, leading to high morbidity and mortality. Despite advances in supportive care, effective therapeutic strategies remain limited. Mesenchymal stem cells derived from the human chorionic membrane, commonly referred to as HCMSCs, represent a highly promising option in the field of regenerative medicine. This is largely owing to their remarkable abilities to modulate the immune system and repair damaged tissues. Nevertheless, the specific biological processes through which these cells exert their influence on lung injury caused by sepsis, especially regarding the modulation of critical molecular signaling pathways, remain to be fully elucidated. A mouse model of sepsis-induced lung injury was established via intraperitoneal lipopolysaccharide (LPS) injection, while human pulmonary microvascular endothelial cells (HPMECs) were stimulated with LPS to mimic an in vitro model. Following the characterization of HCMSCs, the study evaluated their impact on endothelial cell apoptosis, proliferation, and barrier integrity. Inflammatory responses were quantified by measuring key cytokines. To elucidate the molecular mechanism, the study focused on the interaction between the transcription factor SOX18 and MECP2, which was confirmed using chromatin immunoprecipitation and luciferase reporter assays. Finally, the therapeutic efficacy was validated in mice by assessing lung histopathology, edema, and gene/protein expression. Results showed that HCMSCs successfully differentiated into adipocytes and osteoblasts, as confirmed by positive Oil Red O staining and ALP activity. Treatment with HCMSC-conditioned medium (HCMSC
Indexed as
Identifiers
42470544What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.